Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Structure Therapeutics is developing GSBR-1290, an oral small molecule GLP-1 agonist that could potentially address the manufacturing scalability challenges facing peptide-based injectablesthe company has noted its current manufacturing capacity could theoretically supply over 120 million patients [46]
Orngreen et al., 2003
"These products rely on widely held prejudices
Acknowledgements This research was funded by National Basic Research Program of China (973 program 2014CB138600), National Natural Science Fund (31272676 and 31472290), and Program for New Century Excellent Talents in University
US$ 29.11
US$ 21.24
US$ 28.10
US$ 29.17
US$ 20.86
US$ 21.82
US$ 23.23
US$ 23.90
